Cargando…

Intranasal drug delivery: opportunities and toxicologic challenges during drug development

ABSTRACT: Over the past 10 years, the interest in intranasal drug delivery in pharmaceutical R&D has increased. This review article summarises information on intranasal administration for local and systemic delivery, as well as for CNS indications. Nasal delivery offers many advantages over stan...

Descripción completa

Detalles Bibliográficos
Autores principales: Keller, Lea-Adriana, Merkel, Olivia, Popp, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829061/
https://www.ncbi.nlm.nih.gov/pubmed/33491126
http://dx.doi.org/10.1007/s13346-020-00891-5
_version_ 1783641110528131072
author Keller, Lea-Adriana
Merkel, Olivia
Popp, Andreas
author_facet Keller, Lea-Adriana
Merkel, Olivia
Popp, Andreas
author_sort Keller, Lea-Adriana
collection PubMed
description ABSTRACT: Over the past 10 years, the interest in intranasal drug delivery in pharmaceutical R&D has increased. This review article summarises information on intranasal administration for local and systemic delivery, as well as for CNS indications. Nasal delivery offers many advantages over standard systemic delivery systems, such as its non-invasive character, a fast onset of action and in many cases reduced side effects due to a more targeted delivery. There are still formulation limitations and toxicological aspects to be optimised. Intranasal drug delivery in the field of drug development is an interesting delivery route for the treatment of neurological disorders. Systemic approaches often fail to efficiently supply the CNS with drugs. This review paper describes the anatomical, histological and physiological basis and summarises currently approved drugs for administration via intranasal delivery. Further, the review focuses on toxicological considerations of intranasally applied compounds and discusses formulation aspects that need to be considered for drug development. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-7829061
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-78290612021-01-25 Intranasal drug delivery: opportunities and toxicologic challenges during drug development Keller, Lea-Adriana Merkel, Olivia Popp, Andreas Drug Deliv Transl Res Original Article ABSTRACT: Over the past 10 years, the interest in intranasal drug delivery in pharmaceutical R&D has increased. This review article summarises information on intranasal administration for local and systemic delivery, as well as for CNS indications. Nasal delivery offers many advantages over standard systemic delivery systems, such as its non-invasive character, a fast onset of action and in many cases reduced side effects due to a more targeted delivery. There are still formulation limitations and toxicological aspects to be optimised. Intranasal drug delivery in the field of drug development is an interesting delivery route for the treatment of neurological disorders. Systemic approaches often fail to efficiently supply the CNS with drugs. This review paper describes the anatomical, histological and physiological basis and summarises currently approved drugs for administration via intranasal delivery. Further, the review focuses on toxicological considerations of intranasally applied compounds and discusses formulation aspects that need to be considered for drug development. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2021-01-25 2022 /pmc/articles/PMC7829061/ /pubmed/33491126 http://dx.doi.org/10.1007/s13346-020-00891-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Keller, Lea-Adriana
Merkel, Olivia
Popp, Andreas
Intranasal drug delivery: opportunities and toxicologic challenges during drug development
title Intranasal drug delivery: opportunities and toxicologic challenges during drug development
title_full Intranasal drug delivery: opportunities and toxicologic challenges during drug development
title_fullStr Intranasal drug delivery: opportunities and toxicologic challenges during drug development
title_full_unstemmed Intranasal drug delivery: opportunities and toxicologic challenges during drug development
title_short Intranasal drug delivery: opportunities and toxicologic challenges during drug development
title_sort intranasal drug delivery: opportunities and toxicologic challenges during drug development
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829061/
https://www.ncbi.nlm.nih.gov/pubmed/33491126
http://dx.doi.org/10.1007/s13346-020-00891-5
work_keys_str_mv AT kellerleaadriana intranasaldrugdeliveryopportunitiesandtoxicologicchallengesduringdrugdevelopment
AT merkelolivia intranasaldrugdeliveryopportunitiesandtoxicologicchallengesduringdrugdevelopment
AT poppandreas intranasaldrugdeliveryopportunitiesandtoxicologicchallengesduringdrugdevelopment